Fleury Bernard, Rakotonanahary Dominique, Petelle Boris, Vincent Gérard, Pelletier Fleury Nathalie, Meyer Bernard, Lebeau Bernard
Department of Respiratory Medicine, Hôpital Saint Antoine (Assistance Publique Hôpitaux de Paris-Université Paris VI), Paris, France.
Chest. 2004 May;125(5):1761-7. doi: 10.1378/chest.125.5.1761.
Oral appliances (OAs) have been used for the treatment of obstructive sleep apnea syndrome (OSAS), with different degrees of effectiveness having been shown in previous studies. But, in the absence of a consensual recommendation, the method of the determination of effective mandibular advancement varies from one study to another.
We prospectively evaluated an OA titration protocol based on a combined analysis of symptomatic benefit and oximetric recording to guide the progressive mandibular advancement.
University hospital sleep disorders center.
Forty patients with OSAS (mean [+/-SD] apnea-hypopnea index [AHI], 46 +/- 21 events per hour) found on baseline polysomnography, who were intolerant of nasal continuous positive airway pressure, completed all aspects of the study.
Two acrylic appliances connected by Herbst attachments were constructed. The mandible was advanced 1 mm every week until there was a resolution of the symptoms and a reduction in the oxygen desaturation index (ie, the number of desaturations yielding a > 3% fall in pulse oximetric saturation per hour of recording) [ODI] of <10 events per hour of recording or a maximum comfortable limit of advancement was obtained. The final response to OA was evaluated by full polysomnography recording.
A complete response (ie, mean AHI, 5 +/- 3 events per hour; mean snoring reduction [SR], 91 +/- 13%; mean Epworth sleepiness scale [ESS] score, 5 +/- 3) was obtained in 63.6% of patients, and a limited response (ie, mean AHI, 21 +/- 11 events per hour; mean SR, 88 +/- 15%; mean ESS, 6 +/- 3) was obtained in 18.2% of patients. Twenty-five percent of mandibular advancements were motivated by an abnormal ODI (ie, 21 +/- 10 events per hour) despite resolution of the symptoms, while 20% were motivated by persistent symptoms with a normal ODI (ie, 6 +/- 2 events per hour). After a mean duration of 17 +/- 4 months, 34 patients declared that they had used the OA 5 +/- 2 days a week for 89 +/- 19% of their sleep time.
A combination of the patient's subjective evaluation and oximetric score improves the effectiveness of the OA titration procedure.
口腔矫治器(OAs)已用于治疗阻塞性睡眠呼吸暂停综合征(OSAS),先前研究显示其有效性程度各异。但是,由于缺乏共识性建议,有效下颌前移的确定方法在不同研究中各不相同。
我们基于症状改善和血氧饱和度记录的综合分析,前瞻性评估一种口腔矫治器滴定方案,以指导下颌逐步前移。
大学医院睡眠障碍中心。
40例阻塞性睡眠呼吸暂停患者(平均[±标准差]呼吸暂停低通气指数[AHI]为每小时46±21次事件),经基线多导睡眠图检查确诊,且不耐受鼻持续气道正压通气,完成了研究的各个方面。
制作了两个通过Herbst附件连接的丙烯酸矫治器。每周将下颌前移1毫米,直至症状缓解且氧饱和度下降指数(即每小时记录中导致脉搏血氧饱和度下降>3%的饱和度下降次数)[ODI]降至每小时记录<10次事件,或达到最大舒适前移限度。通过全多导睡眠图记录评估对口腔矫治器的最终反应。
63.6%的患者获得了完全反应(即平均AHI为每小时5±3次事件;平均打鼾减少率[SR]为91±13%;平均爱泼沃斯嗜睡量表[ESS]评分为5±3),18.2%的患者获得了有限反应(即平均AHI为每小时21±11次事件;平均SR为88±15%;平均ESS为6±3)。25%的下颌前移是由于症状缓解但ODI异常(即每小时21±10次事件),而20%是由于ODI正常(即每小时6±2次事件)但症状持续。平均17±4个月后,34例患者表示他们每周使用口腔矫治器5±2天,占睡眠时间的89±19%。
患者主观评估和血氧饱和度评分相结合可提高口腔矫治器滴定程序的有效性。